Leerink Partners Begins Coverage on MannKind (NASDAQ:MNKD)

Leerink Partners started coverage on shares of MannKind (NASDAQ:MNKD – Free Report) in a report published on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $8.00 price target on the biopharmaceutical company’s stock. Several other equities research analysts have also recently commented on the stock. Rodman & Renshaw initiated coverage on […]